J. Richard Landis

J. Richard Landis

Auto-generated profile, based on publicly available information

J. Richard Landis

Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA

Research Focus & Metrics

Academic Career Length

52Years (1975-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
PSPeter J. Snyder
Peter J. Snyder
SBShalender Bhasin
Shalender Bhasin
GCGlenn R. Cunningham
Glenn R. Cunningham
AMAlvin M. Matsumoto
Alvin M. Matsumoto
ASAlisa J. Stephens-Shields
Alisa J. Stephens-Shields
SESusan S. Ellenberg
Susan S. Ellenberg
Serum testosterone concentrations decrease as men age, but benefits of raising testosterone levels in older men have not been established. We assigned 790 men 65 years of age or older with a serum testosterone concentration of less than 275 ng per deciliter and symptoms suggesting hypoandrogenism to receive either testosterone gel or placebo gel for 1 year. Each man participated in one or more of three trials — the Sexual Function Trial, the Physical Function Trial, and the Vitality Trial. The primary outcome of each of the individual trials was also evaluated in all participants. Testosterone treatment increased serum testosterone levels to the mid-normal range for men 19 to 40 years of age. The increase in testosterone levels was associated with significantly increased sexual activity, as assessed by the Psychosexual Daily Questionnaire (P<0.001), as well as significantly increased sexual desire and erectile function. The percentage of men who had an increase of at least 50 m in the 6-minute walking distance did not differ significantly between the two study groups in the Physical Function Trial but did differ significantly when men in all three trials were included (20.5% of men who received testosterone vs. 12.6% of men who received placebo, P=0.003). Testosterone had no significant benefit with respect to vitality, as assessed by the Functional Assessment of Chronic Illness Therapy–Fatigue scale, but men who received testosterone reported slightly better mood and lower severity of depressive symptoms than those who received placebo. The rates of adverse events were similar in the two groups. In symptomatic men 65 years of age or older, raising testosterone concentrations for 1 year from moderately low to the mid-normal range for men 19 to 40 years of age had a moderate benefit with respect to sexual function and some benefit with respect to mood and depressive symptoms but no benefit with respect to vitality or walking distance. The number of participants was too few to draw conclusions about the risks of testosterone treatment. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT00799617.)

1 July 2003 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
HFHarold I. Feldman
Harold I. Feldman
LALawrence J. Appel
Lawrence J. Appel
GCGlenn M. Chertow
Glenn M. Chertow
DCDenise Cifelli
Denise Cifelli
BCBorut Cizman
Borut Cizman
JWJackson T. Wright
Jackson T. Wright
Insights into end-stage renal disease have emerged from many investigations but less is known about the epidemiology of chronic renal insufficiency (CRI) and its relationship to cardiovascular disease (CVD). The Chronic Renal Insufficiency Cohort (CRIC) Study was established to examine risk factors for progression of CRI and CVD among CRI patients and develop models to identify high-risk subgroups, informing future treatment trials, and increasing application of preventive therapies. CRIC will enroll approximately 3000 individuals at seven sites and follow participants for up to 5 yr. CRIC will include a racially and ethnically diverse group of adults aged 21 to 74 yr with a broad spectrum of renal disease severity, half of whom have diagnosed diabetes mellitus. CRIC will exclude subjects with polycystic kidney disease and those on active immunosuppression for glomerulonephritis. Subjects will undergo extensive clinical evaluation at baseline and at annual clinic visits and via telephone at 6 mo intervals. Data on quality of life, dietary assessment, physical activity, health behaviors, depression, cognitive function, health care resource utilization, as well as blood and urine specimens will be collected annually. 125I-iothalamate clearances and CVD evaluations including a 12-lead surface electrocardiogram, an echocardiogram, and coronary electron beam or spiral CT will be performed serially. Analyses planned in CRIC will provide important information on potential risk factors for progressive CRI and CVD. Insights from CRIC should lead to the formulation of hypotheses regarding therapy that will serve as the basis for targeted interventional trials focused on reducing the burden of CRI and CVD. E-mail: hfeldman@cceb.med.upenn.edu

1 August 2009 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
JLJames P. Lash
James P. Lash
AGAlan S. Go
Alan S. Go
LALawrence J. Appel
Lawrence J. Appel
JHJiang He
Jiang He
AOAkinlolu Ojo
Akinlolu Ojo
HFHarold I. Feldman
Harold I. Feldman
Background and objectives: The Chronic Renal Insufficiency Cohort (CRIC) Study was established to examine risk factors for the progression of chronic kidney disease (CKD) and cardiovascular disease (CVD) in patients with CKD. We examined baseline demographic and clinical characteristics. Design, setting, participants, & measurements: Seven clinical centers recruited adults who were aged 21 to 74 yr and had CKD using age-based estimated GFR (eGFR) inclusion criteria. At baseline, blood and urine specimens were collected and information regarding health behaviors, diet, quality of life, and functional status was obtained. GFR was measured using radiolabeled iothalamate in one third of participants. Results: A total of 3612 participants were enrolled with mean age ± SD of 58.2 ± 11.0 yr; 46% were women, and 47% had diabetes. Overall, 45% were non-Hispanic white, 46% were non-Hispanic black, and 5% were Hispanic. Eighty-six percent reported hypertension, 22% coronary disease, and 10% heart failure. Mean body mass index was 32.1 ± 7.9 kg/m2, and 47% had a BP >130/80 mmHg. Mean eGFR was 43.4 ± 13.5 ml/min per 1.73 m2, and median (interquartile range) protein excretion was 0.17 g/24 h (0.07 to 0.81 g/24 h). Lower eGFR was associated with older age, lower socioeconomic and educational level, cigarette smoking, self-reported CVD, peripheral arterial disease, and elevated BP. Conclusions: Lower level of eGFR was associated with a greater burden of CVD as well as lower socioeconomic and educational status. Long-term follow-up of participants will provide critical insights into the epidemiology of CKD and its relationship to adverse outcomes.

1 February 1999 in Journal of Urology
Verified
Journal Article
Closed access
PHPhilip M. Hanno
Philip M. Hanno
JLJ. Richard Landis
J. Richard Landis
YMYvonne Matthews-Cook
Yvonne Matthews-Cook
JKJohn Kusek
John Kusek
LNLeroy Jr. Nyberg
Leroy Jr. Nyberg
The lack of a precise working definition of interstitial cystitis may have resulted in the de facto use of the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) "research" definition by clinicians. We evaluated these strict criteria in light of the broader inclusion criteria for patients evaluated in the Interstitial Cystitis Database study to determine their utility in clinical practice as a useful basis for the diagnosis of interstitial cystitis. A total of 379 women who completed screening for the Interstitial Cystitis Database before January 1, 1996 met the basic criteria of urinary frequency, urgency or pain for at least 6 months in duration without a diagnosable etiology. Of these patients 148 underwent cystoscopy and hydrodistention of the bladder as a part of the evaluation. All patients were followed for a minimum of 1 year. Comparisons were made between patients judged to have a clinical diagnosis of interstitial cystitis and those who met the NIDDK research definition of the syndrome. Almost 90% of patients potentially meeting NIDDK criteria are believed by experienced clinicians to have interstitial cystitis, confirming the research value of these criteria in defining a homogeneous population for study. However, strict application of NIDDK criteria would have misdiagnosed more than 60% of patients regarded by researchers as definitely or likely to have interstitial cystitis. The NIDDK criteria are too restrictive to be used by clinicians as the diagnostic definition of interstitial cystitis.

1 December 1977 in Biometrics
Verified
Journal Article
Closed access
JLJ. Richard Landis
J. Richard Landis
GKGary G. Koch
Gary G. Koch
A components of variance model for categorical data from unbalanced designs which is directly analogous to a one-way random effects ANOVA model for quantitative...

1 December 1978 in International Statistical Review
Verified
Journal Article
Closed access
JLJ. Richard Landis
J. Richard Landis
EHEugene R. Heyman
Eugene R. Heyman
GKGary G. Koch
Gary G. Koch